Industry committee  I'll be as brief as I can. I would like to give a specific example of a colleague of mine who was working to start an antiretroviral treatment program with MSF in the early days in Mozambique. His wife, a gynecologist who was working on maternal mortality, said, “We don't even g

Industry committee  Okay. Just one quick point about how the rules did not work, which I think responds a little bit to the question you had raised earlier, Mr. Garneau, and it is related to this as well. It's providing information by Rachel Kiddell-Monroe, who's involved in this. We couldn't actual

Industry committee  I would just say that in the conversations we have.... I guess I'll start back at the beginning. Normally when we're purchasing drugs, we make an order and we get the drugs. There aren't many other steps in that process. When you have to go through the CAMR process, there are ab

Industry committee  Please, feel free.

Industry committee  I'm not sure whether it's a problem in translation, and I apologize that my French is not better, but I don't quite understand what you're saying. What agreements do you mean? Where the market is opened up? Are you speaking about and thinking about the free trade agreements, or a

Industry committee  Yes. Canada's is one of the more developed mechanisms, and the work that's happening right now demonstrates how this ends up being developed. There have been many conversations about what this would actually look like; there's been a lot of engagement in this process. Some other

Industry committee  As has been said, Canada and CAMR are not the only solution to all of these problems. Canada needs to be a player, and Canada has taken a leadership role. There's a lot of mobilization. We've seen all the grandmothers who are here today; we've seen a number of other political act

Industry committee  I understand the question perfectly now. Thank you for the clarification. One of the key components of the competition is the generic competition as compared with the originator drug. That is already competition. If Canada is producing a second-line drug that is not available in

Industry committee  I would largely rest on the comments made by Rachel Kiddell-Monroe in the earlier testimony, because she was the key person based in Canada who was working on this within MSF. But the biggest burden from our side came earlier; that was trying to get a country to come forward and

Industry committee  I'm going to rest on the comments that were made by Rachel Kiddell-Monroe earlier on this, because we were not involved in the actual purchase of the Apotex—

Industry committee  Thank you. Bonjour. Good morning. It is a pleasure and an honour to be here to testify. Médecins Sans Frontières is an international medical humanitarian organization working in over 65 countries, and I'm here to make primarily three points based on our experience. First, quit